Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
19.80B | 19.67B | 19.55B | 18.34B | 17.59B | 17.16B | Gross Profit |
8.31B | 8.21B | 7.92B | 7.18B | 7.17B | 6.77B | EBIT |
2.77B | 2.63B | 2.44B | 2.52B | 2.79B | 2.72B | EBITDA |
3.51B | 3.68B | 3.51B | 3.17B | 3.54B | 3.41B | Net Income Common Stockholders |
2.18B | 1.99B | 1.57B | 1.92B | 2.25B | 2.06B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.47B | 2.89B | 2.49B | 1.45B | 554.00M | 994.00M | Total Assets |
33.59B | 33.09B | 32.45B | 27.54B | 26.31B | 24.23B | Total Debt |
9.18B | 9.38B | 9.86B | 8.25B | 437.00M | 468.00M | Net Debt |
6.73B | 6.50B | 7.37B | 6.80B | -117.00M | -526.00M | Total Liabilities |
24.17B | 24.44B | 25.14B | 18.18B | 9.63B | 9.48B | Stockholders Equity |
9.19B | 8.45B | 7.13B | 9.36B | 16.66B | 14.73B |
Cash Flow | Free Cash Flow | ||||
1.37B | 1.55B | 1.71B | 1.80B | 1.36B | 1.43B | Operating Cash Flow |
1.53B | 1.95B | 2.10B | 2.11B | 1.61B | 1.69B | Investing Cash Flow |
-1.13B | -914.00M | -558.00M | -398.00M | -1.76B | 19.99B | Financing Cash Flow |
-706.00M | -573.00M | -478.00M | -822.00M | -263.00M | -21.54B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $46.53B | 60.09 | 14.07% | ― | 14.78% | 39.33% | |
80 Outperform | $10.05B | 49.27 | 22.50% | ― | 19.98% | 53.10% | |
75 Outperform | $32.58B | 14.96 | 26.32% | 0.18% | 1.55% | 38.51% | |
73 Outperform | $8.99B | 82.29 | 5.77% | ― | 19.21% | 50.06% | |
69 Neutral | $2.80B | 186.17 | 2.53% | ― | 6.79% | -18.52% | |
69 Neutral | $4.12B | 83.80 | 2.30% | ― | 23.40% | ― | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% |
On June 3, 2025, GE Healthcare Technologies Inc. announced the commencement and pricing of an underwritten offering of $1.5 billion in aggregate principal amount of notes. This offering, which includes $650 million of 4.800% Notes due in 2031 and $850 million of 5.500% Notes due in 2035, is expected to be issued around June 9, 2025, and aims to strengthen the company’s financial position. The offering is managed by major financial institutions including Citigroup, J.P. Morgan, and Morgan Stanley, indicating a strong market interest and confidence in GE Healthcare’s financial strategies.
The most recent analyst rating on (GEHC) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on GE Healthcare Technologies Inc stock, see the GEHC Stock Forecast page.
On May 28, 2025, GE Healthcare Technologies Inc. held its annual stockholders meeting where 10 directors were elected for a one-year term. Stockholders also approved executive compensation and ratified Deloitte & Touche LLP as the independent auditor for 2025, while a proposal on termination pay arrangements was not approved.
The most recent analyst rating on (GEHC) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on GE Healthcare Technologies Inc stock, see the GEHC Stock Forecast page.
On March 27, 2025, GE Healthcare Technologies Inc. entered into two new credit agreements with JPMorgan Chase Bank, N.A., providing a total of $3.5 billion in senior unsecured revolving credit facilities. These agreements replace previous credit facilities and include various covenants and events of default, reflecting the company’s strategic financial restructuring. The termination of the previous credit agreements, which provided a combined $3.5 billion in credit, was completed without penalty, marking a significant shift in the company’s financial management approach.